NYSEAMERICAN:SER Serina Therapeutics Q4 2025 Earnings Report $2.10 +0.03 (+1.45%) Closing price 07/27/2026 04:10 PM EasternExtended Trading$2.08 -0.02 (-0.71%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Serina Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASerina Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASerina Therapeutics Announcement DetailsQuarterQ4 2025Date3/25/2026TimeAfter Market ClosesConference Call DateWednesday, March 25, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Serina Therapeutics Earnings HeadlinesSerina Therapeutics, Inc.: Serina Therapeutics Appoints Farrell Simon to its Board of DirectorsJuly 24, 2026 | finanznachrichten.deSerina Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 24, 2026 | globenewswire.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s DiseaseJuly 23, 2026 | markets.businessinsider.comSerina Therapeutics Amends CEO Employment and Compensation TermsJuly 23, 2026 | tipranks.comSerina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's DiseaseJuly 23, 2026 | globenewswire.comSee More Serina Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Serina Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Serina Therapeutics and other key companies, straight to your email. Email Address About Serina TherapeuticsSerina Therapeutics (NYSEAMERICAN:SER), a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.View Serina Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s AI Bubble Could Burst Into Explosive UpsideRefiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear CaseVerizon May Be an AI Infrastructure Stock Hiding in Plain SightApple’s Earnings Setup Puts Its Record Rally and AI Patience to the TestMarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks Healthier Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
